This Article Full Text Full Text (PDF) A correction has been published Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zysman, M. A. Articles by Bapat, B. Search for Related Content PubMed PubMed Citation Articles by Zysman, M. A. Articles by Bapat, B.

(American Journal of Pathology. 2002;160:795-800.)
© 2002 American Society for Investigative Pathology

Short Communication

Considerations When Analyzing the Methylation Status of PTEN Tumor Suppressor Gene

Michele A. Zysman^*, William B. Chapman and Bharati Bapat^*

From the Samuel Lunenfeld Research Institute,^*
MountSinai Hospital; Toronto; the University HealthNetwork,
Toronto; and the Department ofLaboratory Medicine and Pathobiology,
Facultyof Medicine, University of Toronto, Toronto, Ontario, Canada

Correspondence: Address correspondence to Bharati Bapat, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. E-mail: bapat\@mshri.on.ca.

Epigenetic mechanisms of gene silencing, including promoter hypermethylation of tumor suppressor genes, have been shown to contribute to tumorigenesis. PTEN is an important tumor suppressor implicated in the pathogenesis of a number of familial and sporadic cancers. Germline mutations of PTEN predispose to dominantly inherited hamartomatous disorders Cowden syndrome and Bannayan-Zonana syndrome. Somatic PTEN mutations commonly occur in endometrial, breast, prostate, and thyroid tumors. Several investigators have speculated on PTEN promoter hypermethylation as a possible mechanism of PTEN inactivation but data supporting such observations is not forthcoming. The genomic sequence of PTEN is 98% identical to a highly conserved processed PTEN pseudogene (psiPTEN) and this sequence identity extends 841 base pairs into the promoter region. This high degree of homology has made analysis of the methylation status of the PTEN promoter quite challenging. We have investigated the methylation profiles of the promoter region of PTEN in endometrial, breast, and colon cancer cell lines, as well as in a panel of primary endometrial tumors using a combination of methylation-specific polymerase chain reaction, methylation-sensitive restriction analysis, and bisulfite sequencing. Our results show that the pseudogene, and not PTEN, is predominantly methylated in cell lines and tumors. Without careful consideration of the critical nucleotide differences between the two sequences, results obtained from PTEN analysis may not necessarily represent the methylation status of PTEN.

This article has been cited by other articles:

				Y. Zhu, A. Wloch, Q. Wu, C. Peters, A. Pagenstecher, H. Bertalanffy, and U. Sure Involvement of PTEN Promoter Methylation in Cerebral Cavernous Malformations Stroke, March 1, 2009; 40(3): 820 - 826. [Abstract] [Full Text] [PDF]

				J. K. Wiencke, S. Zheng, N. Jelluma, T. Tihan, S. Vandenberg, T. Tamguney, R. Baumber, R. Parsons, K. R. Lamborn, M. S. Berger, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma Neuro-oncol, July 1, 2007; 9(3): 271 - 279. [Abstract] [Full Text] [PDF]

				Q. Yang, C. M. Kiernan, Y. Tian, H. R. Salwen, A. Chlenski, B. A. Brumback, W. B. London, and S. L. Cohn Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome Clin. Cancer Res., June 1, 2007; 13(11): 3191 - 3197. [Abstract] [Full Text] [PDF]

				R. W.K. Chiu, S. S.C. Chim, I. H.N. Wong, C. S.C. Wong, W.-S. Lee, K. F. To, J. H.M. Tong, R. K.C. Yuen, A. S.W. Shum, J. K.C. Chan, et al. Hypermethylation of RASSF1A in Human and Rhesus Placentas Am. J. Pathol., March 1, 2007; 170(3): 941 - 950. [Abstract] [Full Text] [PDF]

				W. Hartmann, B. Digon-Sontgerath, A. Koch, A. Waha, E. Endl, I. Dani, D. Denkhaus, C. G. Goodyer, N. Sorensen, O. D. Wiestler, et al. Phosphatidylinositol 3'-Kinase/AKT Signaling Is Activated in Medulloblastoma Cell Proliferation and Is Associated with Reduced Expression of PTEN. Clin. Cancer Res., May 15, 2006; 12(10): 3019 - 3027. [Abstract] [Full Text] [PDF]

				J. Roman-Gomez, A. Jimenez-Velasco, J. A. Castillejo, X. Agirre, M. Barrios, G. Navarro, F. J. Molina, M. J. Calasanz, F. Prosper, A. Heiniger, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia Blood, October 15, 2004; 104(8): 2492 - 2498. [Abstract] [Full Text] [PDF]

				A. Goel, C. N. Arnold, D. Niedzwiecki, J. M. Carethers, J. M. Dowell, L. Wasserman, C. Compton, R. J. Mayer, M. M. Bertagnolli, and C. R. Boland Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers Cancer Res., May 1, 2004; 64(9): 3014 - 3021. [Abstract] [Full Text] [PDF]

				K. M. Vasudevan, S. Gurumurthy, and V. M. Rangnekar Suppression of PTEN Expression by NF-{kappa}B Prevents Apoptosis Mol. Cell. Biol., February 1, 2004; 24(3): 1007 - 1021. [Abstract] [Full Text] [PDF]

				M. Zysman, A. Saka, A. Millar, J. Knight, W. Chapman, and B. Bapat Methylation of Adenomatous Polyposis Coli in Endometrial Cancer Occurs More Frequently in Tumors with Microsatellite Instability Phenotype Cancer Res., July 1, 2002; 62(13): 3663 - 3666. [Abstract] [Full Text] [PDF]